DaVita Inc. 3rd Quarter 2026 Results

DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026: Consolidated revenues were $3.578 billion.

PRNewsWire • 4 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 10 hours ago

DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates

DaVita HealthCare (DVA) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $2.51 per share a year ago.

Zacks Investment Research • an hour ago

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?

DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.

Zacks Investment Research • Oct 27, 2026

DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks

Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don't know it. The risks are often interconnected: High blood pressure and diabetes can increase the risk of kidney disease, while chronic kidney disease (CKD) often progresses without symptoms.

PRNewsWire • Oct 27, 2026

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know

DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.

Zacks Investment Research • Oct 23, 2026

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.

Zacks Investment Research • Oct 22, 2026

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.

PRNewsWire • Oct 19, 2026

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.

PRNewsWire • Oct 15, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.

Zacks Investment Research • Oct 9, 2026